The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for Teprotumumab (Amgen Australia Pty Ltd)
Active ingredients
Teprotumumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of thyroid eye disease
Therapeutic area
Endocrinology